Compare Dow Inc (DOW) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Dow Inc trades at $29.35 (market cap $20.59B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Dow Inc is far larger — about 4.2× Travere Therapeutics Inc. Common Stock's market cap, and Dow Inc pays a 4.91% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 83 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| DOW | TVTX | |
|---|---|---|
Market Cap | $20.59B | $4.88B |
Volume | 5,540,746 | 1,668,577 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $67.52 |
52-Week Low | $20.95 | $26.79 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | $36.29B | $5.01B |
Dividend Yield | 4.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $29.19, up 3.81% on the day, with a bearish technical signal and neutral oscillators. The company reported negative net income of -$2.62B in 2025, with declining revenue from $56.9B in 2022 to $40.0B in 2025. Recent earnings have beaten expectations, but profitability metrics like ROE (-7.86%) and net margin (-3.13%) remain weak. Analyst consensus is a $33.80 price target with mixed ratings (30.56% Buy, 55.56% Hold).
The outlook is cautious due to persistent margin pressures and high debt levels, though the dividend payout and earnings beats offer some stability. Risks include cyclical demand weakness and rising leverage, but the stock trades below consensus target, suggesting potential upside if operational improvements materialize.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
